Merck Q4 net drops 14 pct. on generic competition

February 5, 2014 by Linda A. Johnson

Merck & Co. reported a 14 percent decline in fourth-quarter profit as generic competition continued to cut into sales of one-time blockbuster medicines, and unfavorable currency exchange rates reduced overseas revenue.

Results fell just short of Wall Street expectations, but company shares appeared to be headed for six-year highs before the opening bell Wednesday after the world's third-biggest drugmaker announced a new and potentially lucrative alliance.

Merck entered into collaboration agreements with three other drugmakers to test its hot experimental cancer drug in combination with theirs. The drug, known only as MK-3475, is in a new class of cancer medicines that are meant to restore the immune systems's natural ability to spot and target cancer cells.

In premarket trading, Merck shares rose $1.11 to $54.62. Shares last traded in that range in early 2008.

Merck reported net income of $781 million, or 26 cents per share, down from $908 million, or 30 cents per share, a year earlier.

The maker of Type 2 diabetes pill Januvia said that excluding one-time items, net income was $2.6 billion, or 88 cents per share. That's a penny shy of Wall Street expectations, according to a poll by FactSet.

Revenue totaled $11.32 billion, down 4 percent. Analysts expected $11.36 billion.

Merck, based in Whitehouse Station, New Jersey, forecast 2014 profit of $2.25 to $2.47 per share, or $3.35 to $3.53 per share, excluding one-time items. Analysts are projecting earnings of $3.46 per share.

"In 2013 we took decisive action to sharpen our focus, reduce our cost structure and advance our innovative research and development," CEO Kenneth Frazier said in a statement. "This year we are excited about the potential of our near- and long-term pipeline, poised for long-term growth and committed to providing continued value to patients, customers and our shareholders."

For the full year, Merck reported of $4.04 billion, or $1.47 per , on revenue of $44.03 billion.

Explore further: Merck 3Q net income falls on charges, lower sales

Related Stories

Merck 3Q net income falls on charges, lower sales

October 28, 2013
Merck & Co. said Monday that its third-quarter profit plunged 35 percent because of competition from generic drugs, lower sales of its top-selling medicine, and restructuring and acquisition charges. It still beat Wall Street's ...

Generic competition cuts Merck's Q1 sales, profit

May 1, 2013
Drugmaker Merck & Co. is reporting lower first-quarter results and cutting its 2013 profit forecast by 15 cents a share. It also is announcing a huge share buyback, up to $15 billion worth of its stock.

Pfizer's 4Q net plunges on charges, sales decline

January 28, 2014
Drugmaker Pfizer said Tuesday that fourth-quarter profit plunged 59 percent because of discontinued operations, restructuring and other charges, and generic competition continuing to siphon off revenue from former blockbuster ...

Merck 2Q profit tumbles on charges, lower revenue (Update)

July 30, 2013
Drugmaker Merck & Co.'s second-quarter profit fell by half as generic competition slashed revenue from several older medicines and sales of its top drug barely budged.

Merck's 2Q net falls on charges, but sales rise

July 27, 2012
Merck & Co.'s second-quarter net income fell 11.4 percent as slightly higher sales were offset by acquisition and restructuring costs. However, the drugmaker beat Wall Street expectations, and Merck shares jumped in early ...

Intel 4Q net income rises 6 pct (Update)

January 16, 2014
Intel's fourth-quarter net income rose 6 percent, as the company offset flat demand for its personal computer chips with higher sales of other products.

Recommended for you

Best of Last Year—The top Medical Xpress articles of 2017

December 20, 2017
It was a good year for medical research as a team at the German center for Neurodegenerative Diseases, Magdeburg, found that dancing can reverse the signs of aging in the brain. Any exercise helps, the team found, but dancing ...

Pickled in 'cognac', Chopin's heart gives up its secrets

November 26, 2017
The heart of Frederic Chopin, among the world's most cherished musical virtuosos, may finally have given up the cause of his untimely death.

Sugar industry withheld evidence of sucrose's health effects nearly 50 years ago

November 21, 2017
A U.S. sugar industry trade group appears to have pulled the plug on a study that was producing animal evidence linking sucrose to disease nearly 50 years ago, researchers argue in a paper publishing on November 21 in the ...

Female researchers pay more attention to sex and gender in medicine

November 7, 2017
When women participate in a medical research paper, that research is more likely to take into account the differences between the way men and women react to diseases and treatments, according to a new study by Stanford researchers.

Drug therapy from lethal bacteria could reduce kidney transplant rejection

August 3, 2017
An experimental treatment derived from a potentially deadly microorganism may provide lifesaving help for kidney transplant patients, according to an international study led by investigators at Cedars-Sinai.

Exploring the potential of human echolocation

June 25, 2017
People who are visually impaired will often use a cane to feel out their surroundings. With training and practice, people can learn to use the pitch, loudness and timbre of echoes from the cane or other sounds to navigate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.